Skip to main content
Denmark
Global Fin Swe Nor Den Ger Cze Svk Pol Nld Bel (nl) Bel (fr) USA
  • Aidian – Your aid in diagnostics
  • Point-of-care test
  • Produkter
  • Om os
  • QuikRead go- Instrument service
  • Indsigtshub
  • Antimikrobiel resistens
  • Messer
Kontakt os Søg
Logo
Kontakt os
  • Point of care
  • Mikrobiologi
  • Molekylær mikrobiologi
  • Hygiejneovervågning
  • RIA / Collagener
  • Hurtigtests
  • Andre
Point of care
  • QuikRead go-systemet
  • microINR
  • FACIT
  • SD BIOSENSOR STANDARD F
  • Nova Biomedical
  • Hangzhou AllTest Biotech Valofia
Læs mere
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go tilbehør
QuikRead go
Mikrobiologi
  • Uricult / Uricult Trio-tests
  • Uricult Vet
  • Cultura M
  • MIKROGEN serologi
  • Meridian Immunoassays
  • Meridian Curian®
  • Reagena
Læs mere
Molekylær mikrobiologi
  • Meridian Revogene®
  • Meridian Alethia®
  • MIKROGEN molecular diagnostics
  • SD BIOSENSOR STANDARD M10
Læs mere
Hygiejneovervågning
  • Easicult
  • Hygicult
  • Cultura M
  • Clean Card PRO
Læs mere
RIA / Collagener
  • UniQ RIA
Læs mere
Hurtigtests
  • Luftvejsinfektioner
  • Mave‑tarm‑sygdomme
  • Seksuelt overførte sygdomme
  • Graviditet og fertilitet
  • Andre
Læs mere
Andre
  • Grifols Promonitor®
Læs mere
  • Aidian i Danmark
  • Bestyrelse og direktion
  • Værdier og kultur
  • Bæredygtighed
  • Karriere
  • Sundhedsemner
  • Om C-reaktivt protein (CRP)
  • Kunde historier
  • Nyheder
  • AMR-interview
  • Spredning af antibiotikaresistente bakterier
  • Understøttende materialer
  • Nyttige links
Modify Selected Code…
Kontakt os Tæt
  • Point-of-care test
  • Produkter
    • Point of care
      • QuikRead go-systemet
      • microINR
      • FACIT
      • SD BIOSENSOR STANDARD F
      • Nova Biomedical
      • Hangzhou AllTest Biotech Valofia
    • Mikrobiologi
      • Uricult / Uricult Trio-tests
      • Uricult Vet
      • Cultura M
      • MIKROGEN serologi
      • Meridian Immunoassays
      • Meridian Curian®
      • Reagena
    • Molekylær mikrobiologi
      • Meridian Revogene®
      • Meridian Alethia®
      • MIKROGEN molecular diagnostics
      • SD BIOSENSOR STANDARD M10
    • Hygiejneovervågning
      • Easicult
      • Hygicult
      • Cultura M
      • Clean Card PRO
    • RIA / Collagener
      • UniQ RIA
    • Hurtigtests
      • Luftvejsinfektioner
      • Mave‑tarm‑sygdomme
      • Seksuelt overførte sygdomme
      • Graviditet og fertilitet
      • Andre
    • Andre
      • Grifols Promonitor®
  • Om os
    • Aidian i Danmark
    • Bestyrelse og direktion
    • Værdier og kultur
    • Bæredygtighed
    • Karriere
  • QuikRead go- Instrument service
  • Indsigtshub
    • Sundhedsemner
    • Om C-reaktivt protein (CRP)
    • Kunde historier
    • Nyheder
  • Antimikrobiel resistens
    • AMR-interview
    • Spredning af antibiotikaresistente bakterier
    • Understøttende materialer
    • Nyttige links
  • Messer
Populære produkter
AllTest Valofia – vektorbårne sygdomme

AllTest Valofia – vektorbårne sygdomme

AllTest Valofia Smart- og Valofia Flow-analysatorer

AllTest Valofia Smart- og Valofia Flow-analysatorer

AllTest Valofia respiratoriske infektioner

AllTest Valofia respiratoriske infektioner

Seneste nyt
Se alt

Hantavirus Andes-udbrud og diagnostik

18. maj 2026 | Nyheder, Produktnyheder

Aidian's bæredygtighedsrapport 2025 er nu offentliggjort

13. maj 2026 | Nyheder

Hurtigtests til professionel brug

4. maj 2026

  • Se alt
  • Ingen resultater fundet
  • Loading...
Nyheder

Hantavirus Andes-udbrud og diagnostik

18. maj 2026 | Nyheder, Produktnyheder

Aidian's bæredygtighedsrapport 2025 er nu offentliggjort

13. maj 2026 | Nyheder

Tilbage til alle nyheder
7. september 2021
Nyheder,
COVID-19

CRP is a marker of severity and prognosis in hospitalized COVID-19 patients

CRP has shown to be a useful marker in COVID-19 patient management in hospitals and intensive care units (ICU). Increased CRP levels are linked to lung injury and predict risk for disease severity and worse prognosis, including mortality1,2. Along with other biomarkers and clinical assessment, CRP enables patient stratification from high to low risk cases and identify those who need intensive care. That will enhance not only patient management but also resource management, hospital flow, and staffing3.

In a study comparing CRP levels in hospitalized patients directed to ICU, those who died had significantly higher CRP levels (206 mg/l) compared to those who survived (114 mg/l)4. Serial measurements of CRP were shown to be a valuable tool in the ICU setting enabling risk stratification and prompt prognosis of the patients. CRP levels increased linearly during the first week of hospitalization peaking at day 5. In patients who survived, CRP levels started to decline earlier, and the peak was lower compared to those who died. If CRP increased more than 20 units/day, the odds for mortality increased significantly. The study concluded that the median CRP values during hospitalization were independent predictors of mortality and correlated with the length of stay in ICU. The rate of CRP increase was more predictive than the maximum CRP value during the first days of hospitalization. Therefore, the daily increase rate of CRP during the first seven days of hospitalization could be used as a tool to predict disease progression and the need for early ICU transfer.

References

  1. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol 2020; 92(11): 2409-2411.
  2. Izcovich A, Ragusa MA, Tortosa F et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One 2020; 15(11): e0241955.
  3. Keddie S, Ziff O, Chou MKL et al. Laboratory biomarkers associated with COVID-19 severity and management. Clin Immunol 2020; 221: 108614.
  4. Sharifpour M, Rangaraju S, Liu M et al. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS One 2020; 15(11): e0242400-e0242400.
Share
Facebook
Twitter
E-mail

Aidian Denmark ApS

Ørestads Boulevard 73,
2300 København S


+45 8610 3020


Forespørgsler
info@aidian.dk


Salg
order@aidian.dk

Selskab
  • Om os
  • Bæredygtighed
  • Karriere
  • Kontakt os
Produkter
  • Point of care
  • Mikrobiologi
  • Molekylær mikrobiologi
  • Hygiejneovervågning
  • RIA / Collagener
  • Hurtigtests
  • Andre
Hurtige links
  • Aidian Academy
  • Indsigtshub
Copyright © 2026 Aidian
  • Data beskyttelse
  • Privatlivspolitikker
  • Cookie politik
  • Sociale medier politik